Cardiac pacemakers
Cardiac electrophysiology
The report presents a summary of reimbursement situation for cardiac pacemakers.
Both single- and dual-chamber pacemakers are considered. Use of pacemakers is considered in complete atrioventricular block and obstructive hypertrophic cardiomyopathy.
Reimbursement analysis covers the following procedures: implantation, replacement and removal of pacemaker.
The only reimbursement within public / statutory health insurance systems is considered.
Manufacturers of devices for cardiac pacemakers include:
Abbott Vascular (Assurity MRI, Endurity MRI)
Biotronik (Enitra, Effecta, Epyra, Estella, Evia, Edora)
Boston Scientific (Essentio, Accolade, Ingenio, Advantio, Vitalio)
Qinming Medical (Qinming)
MicroPort CRM (Kora, Reply, Esprit)
Medico S.p.A. (Gea, Hera, Eos, Sophos, Helios, Mythos, Easy Plus)
Medtronic (Azure, Advisa MRI, Adapta, Micra, Revo MRI SureScan, Sensia, Versa, EnRhythm, EnPulse, Sigma, Kappa)
Pacetronix (Tiranga, Pinnacle, CHARAK, Pinnacle-R)
Vitatron (Vitatron)
Swedish MTP Council has decided to evaluate two new technologies for self-monitoring of atrial fibrillation
In December 2020, Swedish Medical Technologies Product (MTP) Council decided to evaluate new technologies for self-monitoring of atrial fibrillation within the Orderly introduction framework. MTP Council commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to perform a health-economic evaluation of Coala Heart Monitor Pro and KardiaMobile; however, other products may also be considered later.
Upcoming changes in the coverage of medical procedures in Switzerland
On December 22, 2020, the Swiss Federal Office of Public Health announced the changes that will occur to the Services Ordinance (KLV/OPre). The changes concern the general part of the Services Ordinance (KLV/OPre), and all four of its Annexes, which define the coverage of services (List of explicitly evaluated services, List of Medical Aids and Equipment, List of Analyses, List of Medications with Tariff). The updates will enter into force on January 1, 2021. Updates concern among others bariatric surgery, Autologous Chondrocyte Transplantation, ultrasound focused therapy for neurological indications.
Evaluation procedure for endovascular implantation of a stent-graft with valve element in tricuspid valve insufficiency initiated in Germany
On November 9, 2020, in accordance with §137h Paragraph 6 SGB V, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for endovascular implantation of a stent-graft with valve element in tricuspid valve insufficiency within the framework of the early benefit assessment.
2021 DRG (LKF) model published in Austria
In late September 2020, the Austrian version of the DRG system (LKF) 2021 model with the relevant supplementary documents was published in Austria. For 2021, the main changes include the addition of sixteen new procedure codes and the introduction of two new procedure codes for billing in the day-case settings, update of cases flat rates, and adjustments of the cases daily component calculation.
Decisions about intra-DRG reimbursement for medical devices in France in July 2020
The French National Authority for Health (HAS) released new decisions about intra-DRG reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in July 2020. Decisions concern cardiac sutureless valve bioprostheses and implantable devices for the treatment of urinary incontinence.
Decisions about add-on reimbursement for medical devices in France in July 2020
The French National Authority for Health (HAS) released new decisions about add-on and medical aid reimbursement of many medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in July 2020. Decisions concern drug-eluting coronary stents, TAVI, orthopedic appliances, wound dressing, stoma obturator, toric intraocular lens.
Swedish TLV's last call for the ongoing theme survey submissions for orderly introduction for medical technologies
The Swedish Dental and Pharmaceutical Benefits Agency (TLV) is currently performing a theme survey for medical technology products for ischemic heart disease and heart failure. The submissions in relation to this survey will be closed on August 21, 2020
Decisions about add-on reimbursement for medical devices in France in May 2020
The French High Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in May 2020 concern various types of devices, including cardiovascular devices (self-expanding intracranial stents, TAVI), CT navigation kit for CT-guided percutaneous interventions and medical aids. A total of 8 decisions were made.
New guideline on syncope published in Germany
The German Society for Neurology (DGN) has published a new version of the S1 guideline "Syncope." It is valid until January 2025.
Decisions about add-on reimbursement for medical devices in France in April 2020
The French High Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in April 2020 concern various types of devices, for example, cardiovascular and orthopaedic devices, diabetes management systems, and other types of devices. A total of 15 decisions were made.
Clinical guidelines for the appropriate use of cardiac stents released in Tuscany
With a regional decree 381 of March 23, 2020, Tuscany Regional Healthcare has published clinical guidelines on the appropriateness of use and indications on the variability of the consumption of the stents for the arteriopathy of the lower limbs, the carotid stents, and the coronary stents.
Decisions about add-on reimbursement for medical devices in France in March 2020
The French High Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in February 2020 concern various types of devices, for example, cardiovascular and orthopaedic devices, diabetes management systems, and other types of devices. A total of 27 decisions were made.
Positive assessment of Impella 5.0 by HAS in France
On March 30, 2020, the French High Authority for Health, has published the opinion of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS) regarding the Impella 5.0 device. The clinical added value was graded with level II (important) for the post-cardiotomy cardiogenic shock indication. After the negotiation with CEPS, Impella might be the first short-term VAD to enter add-on reimbursement list LPPR.
Decisions about add-on reimbursement for medical devices in France in February 2020
The French High Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in February 2020 concern various types of devices, for example, cardiovascular and orthopaedic devices, diabetes management systems, etc. A total of 6 decisions were made.
Decisions about add-on reimbursement for medical devices in France in January 2020
The French High Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in January 2020 concern various types of devices, mostly for cardiovascular and orthopaedic devices, and medial aids. A total of 29 decisions were made.
Decisions about add-on reimbursement for medical devices in France in December 2019
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in December 2019 concern various types of devices, mostly for cardiovascular devices. A total of five decisions were made.
Decisions about add-on reimbursement for medical devices in France in November 2019
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in November 2019 concern various types of devices, including orthopaedic, and cardiovascular devices. A total of twenty-four decisions were made.
Decisions about add-on reimbursement for medical devices in France in October 2019
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in October 2019 concern various types of devices, including orthopedic, cardiovascular devices, and hearing aids. A total of twenty-four decisions were made.
Decisions about add-on reimbursement for medical devices in France in September 2019
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in September 2019 concern various types of devices, including orthopedic, cardiovascular devices, and hearing aids. A total of eighteen decisions were made.
Decisions about add-on reimbursement for medical devices in France in July and August 2019
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in July and August 2019 concern various types of devices, including orthopedic, cardiovascular, and blood glucose meters. A total of 29 decisions were made.
Two procedures can use analogous coding since July 2019 in Switzerland
Explanation about the coding of selective intravascular radiotherapy (SIRT) with microspheres labeled with holmium-166, and of creation of intracardiac septal defect with implantation of an interauricular implant (percutaneous transluminal) in Switzerland was released by SwissDRG on July 26, and July 31, 2019, respectively.
Decisions about add-on reimbursement for medical devices in France in June 2019
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in June 2019 concern various types of devices, including orthopedic, cardiovascular and diabetes devices, and cochlear implants. A total of 32 decisions were made.
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in May 2019 concern various types of devices, including orthopedic, cardiovascular and diabetes devices.
G-BA commissioned a trial study for heart failure telemedical monitoring
The Federal Joint Committee (G-BA) has signed a further contract for scientific monitoring and implementation of a trial study for NYHA III heart failure therapy optimization by means of continuous blood pressure measurement and monitoring using an implanted sensor in the pulmonary artery.
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in April 2019 concern orthopedic devices, coronary stents, ventricular assist devices, remote monitoring systems in cardiovascular field, cochlear implants, bronchial thermoplasty device.
The French National Authority for Health (HAS) regularly publishes new decisions about add-on reimbursement for medical devices. The decisions made in March 2019 concern various types of devices, including orthopedic, cardiovascular (coronary stents), ENT and other products.
MTRC has released European reimbursement report for cardiac pacemakers in 11 EU countries
The report presents a summary of reimbursement situation for cardiac pacemakers. Both single- and dual-chamber pacemakers are considered. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.
New catalog for centralized purchasing platform for health products in Spain
On February 19, 2019 the new "Catalog of Goods and Services" for the centralized purchasing platform was presented to the regional health authorities by the Minister of Health. This new catalog includes up to 25,000 items, including drugs and health products.
The French National Authority for Health (HAS) regularly publishes new (32 in total) decisions about add-on reimbursement for medical devices. The decisions made in February 2019 concern various types of devices, including multiple orthopedic, cardiovascular and other devices.